Drugs / CD19 and CD22 targeted prime CAR- T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04782193 | May 2021 → Dec 2023 | lymphoma | Chongqing Precision Biotech Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 and CD22 targeted prime CAR- T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04782193 ↗ |
| Modality | Cell therapy | “CD19 and CD22 targeted prime CAR- T cells” NCT04782193 ↗ |
| Route | Intravenous | “administered intravenously” NCT04782193 ↗ |
| Target | CD19 | “CD19 and CD22 targeted prime CAR- T cells” NCT04782193 ↗ |
| Target | CD22 | “CD19 and CD22 targeted prime CAR- T cells” NCT04782193 ↗ |